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I  Summary 
 
Since the 70s the tricyclic amine amantadine is used as anti Parkinson adjuvans as it could 
substantially reduce parkinsonian symptoms. Parkinson´s disease is characterized by a loss of 
dopaminergic fibers of the substantia nigra pars compacta but also the noradrenaline rich fibers 
of the locus coeruleus are affected by  neuronal cell damage. Drugs which are restoring 
dopamine levels in the early stage and noradrenaline levels in later stages are clinically useful. 
In the 70s it was revealed that amantadine is able to increase central dopamine and 
noradrenaline levels due to enhanced release or uptake blockade of the dopamine and 
noradrenaline transporter (DAT and NAT). 
 
In the following work we wanted to assess its role as a possible releaser like amphetamine or 
uptake blocker on the human DAT or NAT by means of uptake experiments, superfusion 
experiments and patch clamp, as this was not clarified in the previous studies. The second part 
of my work was dedicated to the design of n-methyl-d-aspartate (NMDA) receptor (NR1/2A) 
expressing HEK 293 cells whose NMDA receptor is autotoxic. In several studies amantadine 
also showed NMDA receptor blocking properties. The potency of amantadine to suppress 
NMDA receptor mediated autotoxicity was compared with other test drugs like ketamine in 
cell viability assays. The ability of amantadine to block the entry of the NAT toxin 1-methyl-4-
phenylpyridinium (MPP+) was also examined. 
 
Uptake experiments showed that amantadine is 15 times more potent in inhibiting the NAT 
than the DAT. In superfusion experiments amantadine clearly demonstrated a releasing action 
with a maximum effect less half than that of amphetamine. Patch clamp also revealed that 
amantadine was a releasing drug at the NAT. On dopamine transporter expressing cells 
amantadine produced no significant inward currents suggesting a lower affinity at the DAT 
which is in agreement with the uptake data. In the cell viability assay ketamine blocked 
cytotoxicity in the µmol range restoring cell viability to more than 90% of that of cells without 
NMDA receptor induction. Contrary to this, amantadine was only partly protective at 300 µM. 
In NAT expressing cells the tricyclic antidepressant desipramine had the highest potency in 
blocking MPP+ induced toxicity. Amantadine was less potent than desipramine but 100µM had 
a significant effect and 300µM a strong protective effect restoring cell viability to 80% of 
vehicle treated cells. 
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II  Zusammenfassung 
 
Seit den 70er Jahren wird das tricyklische Amin Amantadine als Hilfsmittel bei der Parkinson 
Erkrankung verwendet da es wesentlich dazu beiträgt Parkinson Symptome zu reduzieren. Die 
Parkinson Erkrankung ist gekennzeichnet durch einen Verlust von dopaminergen Nervenfasern 
der Substantia nigra pars compacta aber auch Noradrenalin-hältigen Fasern des locus coeruleus 
die auch von Nervenzellschädigung betroffen sind. Substanzen die den Dopaminspiegel 
wiederherstellen in der Anfangsphase der Krankheit sowie den Noradrenalin Spiegel in 
späteren Stadien sind klinisch relevant. In den 70er Jahren konnte gezeigt werden, dass 
Amantadin fähig ist den Dopamin und Noradrenalinspiegel anzuheben durch Blockade des 
Noradrenalin und Dopamintransporters (NAT und DAT) oder durch vermehrte Freisetzung 
dieser Katecholamine.  
 
In der nachfolgenden Arbeit wollten wir herausfinden, ob Amantadin wie Amphetamin 
freisetzende Eigenschaften besitzt oder  wie ein Wiederaufnahmehemmer am DAT und NAT 
wirkt. Die Umsetzung erfolgte mittels Uptakeexperimenten, Superfusions- experimenten und 
Patch clamp, da der genaue Mechanismus in den bisherigen Studien nicht untersucht wurde. 
Der zweite Teil der Arbeit bestand in der Herstellung von N-methyl-d-Aspartat (NMDA) 
Rezeptor (NR12A) exprimierenden HEK 293 Zellen deren neuer Rezeptor autotoxisch ist. In 
einigen Studien konnte gezeigt werden, dass Amantadin als NMDA Rezeptorblocker wirkt. Die 
Potenz von Amantadin, NMDA Rezeptor vermittelnde Autotoxizität zu unterdrücken wurde in 
Vitalitätsversuchen an diesen Zellen untersucht. Die Fähigkeit von Amantadin, das NAT Toxin 
1-methyl-4-phenylpyridinium (MPP+) zu blockieren wurde ebenfalls untersucht. 
 
Die Uptake Experimente zeigten, dass Amantadin 15 mal potenter war bei der Hemmung des 
NAT als des DAT. Bei den Superfusionsexperimenten konnte deutlich bewiesen werden, dass 
Amantadin einen Freisetzungseffekt besitzt mit einem Maximalwert der weniger als halb so 
groß ist wie der von Amphetamin. Mit Patch clamp konnte auch gezeigt werden, dass 
Amantadin ein freisetzendes Substrat am NAT ist. Bei den DAT exprimierenden Zellen 
produzierte Amantadin keine signifikanten Einwärtsströme was mit einer niedrigeren Affinität 
am Dopamintransporter zu erklären ist, übereinstimmend mit den Uptake Messergebnissen. Im 
Vitalitätsversuch konnte Ketamin die Cytotoxizität im µmolaren Bereich zu mehr als 90% 
unterbinden im Vergleich zu Zellen ohne NMDA Rezeptor Bildung. Im Gegensatz dazu war 
Amantadin  bei 300 µM nur teilweise protektiv. 
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In NAT exprimierenden Zellen hatte das trizyklische Antidepressivum Desipramin die höchste 
Potenz in der Blockierung der MPP+  induzierten Toxizität. Amantadin war niederpotenter als 
Desipramin, obgleich 100 µM einen signifikanten Effekt verursachten und 300µM einen 
starken protektiven Effekt zeigten der 80% der Zellen verglichen mit Vehikel behandelten 
Zellen  wiederherstellte.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  6 
1  Introduction 
 
1.1  Amantadine 
 
1.1.1  Chemistry of amantadine 
The tricyclic amine amantadine is a derivative of adamantan, which itself is a cycloalkane. The 
molecule consists of adamantane backbone that is substituted at one of the four methylene 
positions with an amino group. Its known formally as 1-aminoadamantane (Fig. 1).             
 
                                                         
                                                            Fig. 1: structural formula of amantadine 
 
Amantadine is well absorbed and has a complete biovailability. In men, the maximum plasma 
levels are reached within 1-12 h after oral administration. The mean half life is 10-14 hours, in 
renal impairment up to 7-10 days. There is a negligible metabolism, thus elimination of 
amantadine is predominantly renal as unchanged compound (90%, Aoki and Sitar 1985) The 
drug is highly lipophilic, a passage through the blood-brain barrier depends on the degree of 
saturation. Toxicological studies indicate a main effect in the central nervous system .(Vernier, 
et al. 1969). Since the 1960s it has been widely used for the prophylaxis and treatment of 
influenza A. Amantadine acts as an inhibitor of the ionchannel M2, which is one of three 
important viral integrated membrane proteins. The M2 channel protein is an essential 
component of the viral envelope because of its ability to form a highly selective, pH-regulated, 
proton-conducting channel, which is necessary for viral uncoating. In the presence of 
amantadine, viral uncoating is incomplete, and the ribonucleoprotein core fails to promote 
infection (Basler 2007). 
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1.1.2  Amantadine as anti-parkinson adjuvant 
Furthermore, observations  in the 70s showed, that amantadine is beneficial for the treatment of 
Parkinson disease (PD), as it could substantially reduce parkinsonian symptoms (Boman and 
Porras 1970; Grelak, et al. 1970). Parkinson is a degenerative disease of the brain which is 
characterized by a progressive loss of dopaminergic fibers in the substantia nigra pars 
compacta innervating the caudatus nucleus and the putamen which together are called striatum, 
beeing a part of the extrapyramidal motor system. Moreover, other systems like the 
noradrenaline (NA) containing locus coeruleus (LC) neurons are also subject of degeneration, 
which contributes to the cardinal symptoms tremor, rigor and akinesia (Rommelfanger and 
Weinshenker 2007). The parkinsonian symptoms start if 70% of the substantia nigra pars 
compacta neurons which project to the striatum get lost. The remaining nigrostriatal neurons 
are apparently able to compensate a loss by increasing the synthesis and release of dopamine 
(DA). A higher postsynaptic DA receptor sensitivity also contributes to this mechanism of 
compensation (Rinne 1982). 
 
How leads the degeneration of dopaminergic neurons to the clinical symptoms? The corpus 
striatum contains GABA-neurons and a smaller number of cholinergic interneurons which are 
normally blocked by dopamine. In the case of PD the cholinergic neurons are disinhibited 
triggering an imbalance between cholinergic and dopaminergic neurotransmission. This is a 
fundamental step to the clinical symptomatology (Lusis 1997). 
 
The picture is even more complicated if you consider the complex wiring of the extrapyramidal 
motoric basal ganglia, as a key controller of selection and processing of currently required 
motor and higher integrative non-motor operation schemes. In the same time, currently not 
required activation patterns are suppressed. The basal ganglia can be understood as complex 
loop going from the cortex over the basal ganglia to the thalamus and back to the cortex (Fig. 
2). 
 
Let us have a look on the function and the components of the basal ganglia in normal and 
pathological conditions to assess the therapeutical potential of amantadine. From the whole 
cortex glutamatergic neurons are going to the striatum which is the entry nucleus of the basal 
ganglia. There, they activate GABAergic and cholinergic neurons. The further way to the 
thalamus is complicated and comprises a direct and indirect pathway (Schmidt 1995). The 
direct pathway is excitatory while the indirect pathway is inhibitory.  
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The direct pathway involves GABAergic neurons of the striatum the globus pallidus medialis 
(Gpm) and the substantia nigra pars reticularis (Snpr). GABA neurons of the striatum are 
activated through DA coming from fibres of the substantia nigra pars compacta (Snpc) , 
activating D1-receptors. 
 
This GABAergic projection from the striatum to a GABAergic projection from the Gpm to the 
motor thalamus leads to a disinhibition of motor thalamic glutamatergic neurons, and thus 
facilitates movement. The same molecular mechanism and neuronal architecture is true for 
GABA projections of the striatum to the Snpr, which also triggers activation of the motor 
thalamus. 
 
The indirect connection is a little bit more complicated. Some GABA neurons of the striatum 
are inhibited through D2-receptors in the presence of DA, this is the case if the first pathway is 
active. If DA levels decline, the GABA neurons which are responsible for the second pathway 
are activated. These GABA neurons project to the globus pallidus lateralis, where they inhibit 
GABA-type neurons projecting to the subthalamic nucleus (STN). The inhibition of the 
inhibition leads again to the disinhibition of downstream located neurons, which are 
glutamatergic. The STN depicts a regulation link of the activities from GABA neurons of both 
Gpm and Snpr, which means that increased firing leads to enhanced GABA-ergic transmission 
and in fact weakens the activity of the motor thalamus. 
 
In the pathological absence of DA, the activity of  GABA neurons of the direct pathway is 
reduced and the GABA neurons of the indirect pathway are enhanced (McAuley 2003). The  
outcoming filterfunction of sensomotoric signalling to the cortex is increased by a dampening 
of the motor thalamus. This results in rigor, tremor and akinesia which are the major symptoms 
of PD. 
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Fig. 2: extrapyramidal-motoric basal ganglia loop in healthy  (left picture) and in  case   of    Parkinson  
                    (right picture) arrow tips: activation; dotted lines:  activity reduction; doubled lines: activity increase; 
                    glutamate: red; GABA: blue; dopamine: green; acetylcholine: yellow;1 ,2,3: actions of dopamine  and 
                    impaired  functions in case of deficiency of dopamine  
 
In literature amantadine is described as uncompetitive NMDAR antagonist (Kornhuber et al., 
1991; Stoof et al. 1992; Blanpied, Clarke et al. 2005), which may explain its effect in PD. In 
the case of PD subthamalic glutamatergic efferents to Gpm and Snpr are disinhibited and push 
GABA neurons through NMDAR. This might explain why NMDAR blockers like amantadine 
and memantine reduce PD symptoms. In the case of mild symptoms it is therapeutically usefull 
to begin PD therapy with amantadine or memantine in combination with muscarine recptor 
antagonists. If this medication is not longer able to restrain the functional limitations of PD 
symptoms one may add a DA receptor agonist. If this first line therapy fails it is useful to add 
the currently most powerful weapon (-)-3,4-dihydroxypenylalanine (levodopa) with 
decarboxylase-blockers. Levodopa can cross the blood-brain barrier and is intracellulary 
decarboxylated to DA, while the decarboxylase blocker remains in the periphery, thereby 
preventing an enzymatic transformation of levodopa to DA outside the brain. There a higher 
DA level is associated with unwanted side effects such as unstable blood pressure or cardiac 
side effects. 
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1.1.3  Dyskinesia in PD 
Levodopa and DA agonists are the mainstay of pharmacological therapy for PD and are able to 
control PD symptoms adequately for a prolonged period of time. However, chronic therapy 
with these medications is often associated with the development of choreiform, involuntary 
movements called drug-induced dyskinesias (DID). They are defined as abnormal, excessive 
and involuntary movements. As the duration of dopaminergic treatment increases to a mean of 
6 years, over two-third of patients will develop DID (Lim 2005).  
 
DID represents a major source of disability and anxiety among the patients. Moreover, it acts 
as a dose limiting factor which prevents satisfactory control of PD symptoms. As described 
before, an abnormal lack of DA leads to hyperactivities of the output nuclei Gpm and Snr 
induced by STN leading to excessive inhibition of the motor thalamus and the cortex which in 
turn causes an akinetic crises and other parkinsonian features. Levodopa is hypotesized to 
normalize the direct and indirect striatal output pathways, thereby reducing Snr and Gpm 
overactivities. 
 
The current state of the art models of DID suggest on the other hand that an excessive decrease 
in Snr and Gpm activities disinhibit the motor thalamus giving rise to an abnormal increase in 
cortical drive and hardly controllable choreiform motor movements (Papa et al. 1999). But 
what is responsible for such abnormal alterations? The most accepted hypothesis is nigro-
striatal denervation, coupled with non-physiological dopaminergic stimulation. A chronic 
pulsatile stimulation of DA receptors leads to persistent changes in the basalganglia which in 
turn favours an abnormal pattern of discharges in the circuitry and consequently causes 
dyskinesia. 
 
However, further studies indicate that things are not that simple, because of a variety of 
neurochemical and molecular factors contributing to DID. One group argues that development 
of DID is linked with the appearance of D3 receptor mRNA binding sites in the denervated 
caudate and putamen from which this receptor subtype is normally absent (Bordet et al. 1997) . 
GABA neurotransmission is also widely seen in the basal ganglia. There are also changes in 
this system due to DA depletion. Chronic non-intermittent levodopa therapy causing pulsatile 
DA stimulation is shown to cause up-regulation of GABAA receptors. In post mortem samples 
Calon and Di Paolo (2002) have shown increased GABAA receptors content in the Gpm in 
dyskinetic PD patients, compared to nondyskinetic patients. 
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1.1.4          N-methyl- D-aspartate receptors and glutamate in DID  
 
1.1.4.1        The NMDA receptor 
The N-methyl-D-aspartate receptor (NMDAR) is a specific type of ionotropic glutamate 
receptor often colocalized with DL-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors in the brain. N-methyl-D-aspartate is a selective agonist binding to the 
NMDAR but not to other glutamate receptors. 
 
NMDARs have unique properties, they are both ligand gated and voltage dependent. For the 
activation of the nonselective cation channel first glutamate and glycine must bind on 
NMDAR. As NMDARs are blocked with extracellular Mg2+, little ionic current passes. After 
glutamate release AMPA channels are activated being a pore for Na+. If current flows through 
AMPA channels the membrane is depolarized. If glutamate release coincides with 
depolarisation sufficient to displace the Mg2+ ions from the NMDAR, a flow of Na+ and small 
amounts of Ca2+ ions into the cell and K+ out of the cell takes place (Bear 2001). This process 
plays a pivotal role in LTP, a process which is implicated in molecular learning processes like 
memory and pathologic processes like chronic pain and addiction.  
 
The NMDAR consists of two NR1 and NR2 subunits forming a heterotetramer. There are eight 
splice variants of the NR1 subunit, but NR1-1a is the most abundantly expressed form. The 
NR2 subunit got also various isoforms termed NR2A through D. The NR1 subunits bind the 
coagonist glycine and NR2 subunits bind the neurotransmitter glutamate (Cull-Candy et al. 
2001).  
 
Antagonists of the NMDAR are used as anesthetetics and have often hallucinogenic properties 
like ketamine and PCP, but there exist also others with therapeutic effects against 
neurodegenerative diseases like memantine and amantadine as well as anticraving therapeutics 
like acamprosat. 
 
 
1.1.4.2 Glutamate receptor mediated mechanisms in DID 
Glutamate is the main excitatory neurotransmitter in the basal ganglia circuitry. As 
dopaminergic denervation progresses the glutamatergic neurotransmission is thought to 
become overactive.  
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Attempts to suppress it with manipulation of common dopaminergic drugs often fail, leading to 
the exploration of alternative approaches. Glutamate receptor mediated mechanisms have been 
proposed as contributing factors in levodopa- related motor complications in animal models. 
All glutamate receptor subtypes (NMDA, AMPA, Kainate and metabotropic) are found in the 
basal ganglia circuitry although NMDA receptors may play a key role in the development of 
DID. NMDA receptor binding was shown to be increased by 53% in the putamen of PD 
patients with motor fluctuations when compared to those without (Calon et al. 2003).  
 
One major mechanism to improve dyskinesia could be the blockade of NMDARs, but the 
toxicity of clinically available glutamate antagonists generally precludes full characterisation of 
their antidyskinetic potential. As amantadine is a save and widely used antiparkinsonian agent 
which is known to be an uncompetitve NDMA receptor blocker (Kornhuber et al., 1991; Stoof 
et al. 1992), its antidyskinetic potential has been evaluated in animal models as well as in 
human studies. 
 
The group of Thomas Chase (Blanchet et al. 1998) used MPTP monkeys which showed 
choreiform and dystonic dyskinesia after a long-time of levodopa administration. When 
administered with a relatively low dose of levodopa, amantadine showed a total suppression of 
choreiform dyskinesia as well as a substantial reduction of dystonic dyskinesia. With a high 
dose of levodopa amantadine had a smaller but still significant effect on dyskinesia without 
worsening parkinsonian scores. The positive effects of levodopa also remained without being 
disturbed by NDMA receptor blockade. 
 
In a double-blind, placebo controlled, cross-over study Verhagen, L. and colleagues (Verhagen 
Metman et al. 1998) wanted to assess the anti dyskinetic potential of amantadine in 18 patients. 
In the 14 patients completing this trial, amantadine reduced dyskinesia severity by 60% 
compared to placebo, without altering the antiparkinsonian effect of levodopa. It is unclear, if 
amantadine might be selective for a specific subunit of the NDMA receptor complex. Drugs 
which are in development selectively targeting certain subunits are supposed to give even 
greater benefits to the patients without increasing adverse effects. However, based on the 
current results, a large proportion of patients with advanced PD and motor complications can 
be expected to benefit from the addition of amantadine to their standard medications. 
Nevertheless, amantadine may have also side effects including nervousness, anxiety, agitation, 
insomnia and difficulty in concentrating. 
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1.2  Implications of the noradrenergic system in PD 
The main hallmark in PD is the loss of nigrostriatal DA neurons leading to the well known 
symptoms akinesia, tremor and rigor. As described before, the gold standard in therapy is 
levodopa which ameliorates those motor symptoms. It could have been shown that several of 
the symptoms of PD, mostly those which appear in the later stages, do not respond 
satisfactorily to levodopa treatment. Symptoms like cognitive disorders, postural instability, a 
frozen gait and autonomic dysfunction are believed to be rather of noradrenergic than 
dopaminergic nature. Post-mortem studies have shown that also noradrenergic 
neurotransmission is impaired in PD. There is a decrease in NA-levels combined with a 
neuronal loss in the locus coeruleus  of patients with PD (Gesi et al. 2000).The site where NA 
nuclei are located is mainly the LC or A6 cell group and medullary nuclei designated as 
A1,2,A5 and A7 (Fig. 3). The LC projections go to the whole neocortex and the limbic 
forebrain (amygdala, septum, hippocampus).  
 
Cell groups from A1-A7 inervate mostly the septum and hypothalamus. In addition a 
descending pathway innervates the spinal cord which provides autonomic functions. The LC 
projections are widespread in the central nervous system and may have pervasive effects at 
diverse terminal regions such as the neocortex and limbic areas. These facts suggest the 
implication of the NA system in several processes such as motor function, learning, memory, 
mood and autonomic functions which are all together impaired in PD. 
                           
                          Fig. 3: Noradrenergic nuclei and their projections in the rat brain. LC = locus coeruleus 
 
A large body of evidence indicates that noradrenergic systems interact with dopaminergic 
systems in the brain. Electrophysiological findings suggest that LC neurons can stimulate 
nigral neurons. Noradrenergic neurons exert a tonic excitatory influence on SNc DA neurones 
since experimental lesions of the LC with neurotoxins decrease the release of DA in the rat 
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striatum as measured by microdialysis in vivo (Lategan et al. 1992). Thus, there is a rationale 
for pharmaceutics enhancing central noradrenergic function. Studies have shown a possible 
neuroprotective effect of so called α2-adrenoceptor antagonists. 
 
  
1.2.1  Noradrenergic α2 autoreceptors 
Alpha-2
 
receptors are located both post and presynaptically. The significance of presynaptic 
receptors is their ability to modulate transmitter release (Langer 1980). Presynaptic α2 receptors 
are autoreceptors which are excited by NE released by the respective neuron. The autocrine 
activation of α2 adrenoceptors inhibits NE release. Several possible mechanisms are supposed 
to be responsible for a diminution of NE release. The coupling of α2 autoreceptors with a Gi-
protein leads to an inhibition of adenylate cyclase, resulting in a decrease of intracellular cAMP 
and Ca2+ concentration. It attenuates the rate of   Ca2+ entry through inhibition of voltage gated 
Ca2+ channels and inhibits thus vesicle fusion. A further activation and opening of K channels 
triggers hyperpolarisation of the neuron terminals. On the other hand autoreceptors of the β2 
subtype mediate facilitation of NE release due to stimulation of adenylate cyclase with a Gs 
protein, leading to an increase in cAMP and a subsequent increase in intracellular Ca2+ 
concentration.  
 
The presence of presynaptic facilitatory and inhibitory adrenergic receptors on the same nerve 
terminals provide a fine-tuning control of stimulus-evoked NE release which could be 
influenced in favour of an increased NE release by α2 adrenoceptor blockers like idazoxan or 
yohimbine (Langer 1980). 
 
 
1.2.1.1 α2-adrenoceptor blockers in PD 
In humans a parallel group, double blind, randomised, placebo controlled study showed, if 
single doses of 25 and 100ug/kg idazoxan were administrated, an improvement of the unified 
Parkinson´s disease rating scale motor score (by 25%) in 15 patients with PD (Peyro-Saint-Paul 
et al. 1995). The most influenced symptom (50-70% improvement) was rigidity, while tremor 
was not responsive to the drug.  
In a study on MPTP monkeys rendered dyskinetic by high doses of levodopa an antidyskinetic 
effect have been observed without compromising the antiparkinsonian efficacy of levodopa 
(Bezard et al. 1999). In a study on 18 patients with Parkinson's disease receiving long term 
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levodopa treatment, the severity of L-DOPA-induced dyskinesia improved after 20 mg 
idazoxan pretreatment, while there was no concommittant worsening in the antiparkinsonian 
response to levodopa (Rascol et al. 2001). The exact mechanism of action has yet to be 
elucidated. It could be hypotesized that α2-adrenoceptor blockers located on LC neurons, 
leading to activation of the LC-SNc pathway resulting in an enhanced compensatory activity of 
surviving DA neurons. 
 
Although α2-adrenoceptor antagonists may provide some benefit to patients with PD, they also 
can induce several side effects. In the periphery they can mediate troublesome cardiovascular 
effects by enhancing sympathetic tone, leading to increased blood pressure and tachykardia. At 
the central level α2-adrenoceptor antagonists can promote anxiety states and increase vigilance. 
Long term clinical studies are necessary to assess the safety of α2-adrenoceptor antagonists in 
the treatment of PD. 
 
 
1.3  Effects of amantadine on DA and NE neurotransmission 
According to the previous paragraph, enhanced NE and DA transmission by means of 
pharmaceutical manipulation can help to relief parkinsonian symptoms. Therefore, already in 
the 1970s the effects of amantadine on DA/NA uptake and release were intensively examined.  
The literature contains evidence that amantadine may act by releasing catecholamines (Scatton 
et al. 1970, Spilker et al. 1974), or by inhibiting the neuronal uptake of catecholamines 
(Thornburg and Moore 1973, Fletcher and Redfern 1970). 
  
In a recent study, the effect of amantadine on extracellular DA levels in the rat striatum was 
studied using an in vivo microdialysis (Takahashi et al. 1996). Amantadine was applied 
through dialysis probe for 20min. The extracellular DA content was increased in a dose 
dependent manner. The findings of this study suggest that amantadine might influence DA 
concentration by facilitating DA release from striatal dopaminergic nerve endings. 
 
In a rat model of PD, levodopa derived extracellular striatal DA levels were measured by in 
vivo microdialysis after unilateral denervation by 6-hydroxydopamine (Arai et al. 2003).  After 
DA levels became stable all rats were injected with the decarboxylase inhibitor benserazide and 
divided into three groups and amantadine 10 or 30mg/kg, or vehicle was administered 15min 
prior to levodopa injection (50 mg/kg, 30 min after benserazide injection). A single dose of 
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levodopa given to the 6-OHDA-lesioned rats increased the DA levels to 286 fmol/sample at 80 
min after levodopa administration. Pre-treatment with amantadine led to a higher value of 388 
fmol/sample at 100 min in amantadine 10mg/kg group. The highest level was obtained in the 
30mg/kg group with 670 fmol/sample. This is the first experimental study which exhibits the 
effect of amantadine on the metabolism of exogenous L-DOPA in rats with dopaminergic 
denervation. 
 
In an earlier study Farnebo and colleagues (Farnebo et al. 1971) wanted to assess the DA and 
NA releasing action of amantadine in the central and peripheral nervous system. In  
biochemical superfusion experiments of tissues from untreated rats they studied the effect of 
amantadine. [3H]NA uptake was studied in isolated irides and slices of the cerebral cortex and 
the [3H]DA uptake in neostriatal slices. The irides were superfused after incubation with 
[3H]NA for 30 min and then electrically stimulated with biphasic pulses. The tritium efflux was 
higher if 10 µM amantadine was present in the buffer. Neostriatal slices were superfused after 
incubation with [3H]-DA for 40 min and then stimulated for 2 min. In this case there is also a 
higher tritium efflux in the presence of 10 µM amantadine. 
 
In functional experiments rats with a 6-hydroxydopamine-induced unilateral degeneration of 
nigrostriatal DA neurons were treated with 50mg/kg amantadine. In these rats supersensitivity 
of DA receptors can be observed on the denervated site; DA receptor stimulating agents such 
as apomorphine increase the DA receptor activity preferentially on the denervated side forcing 
the rat to rotate to the intact side (Marshall and Ungerstedt 1977). In contrast, DA releasing 
agents, such as amphetamine only increase DA receptor activity on the intact side forcing the 
rats to rotate to the denervated side (Fig. 4, Ungerstedt, 1971). 
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                                  Fig. 4: Rotational behaviour of rats with unilateral degenerated nigrostriatal 
                                            DA neurons induced by 6-OH dopamine. Apomorphine causes rotation away 
                                            from the lesion due to activation of supersensitive dopamine receptor signalling 
                                            on the lesioned side. Amphetamine causes rotation toward the lesion due to enhanced 
                                           dopamine release from the unlesioned side (Ungerstedt, 1971). 
                                             
Amantadine made the rats turn to the lesioned site. This fact, together with the previous 
superfusion experiments, suggested that amantadine is about 25-50 times less potent a releaser 
than amphetamine. Amphetamine exerts its action through the closely related monoamine 
transporters, dopamine and noradrenaline transporter. If amantadine acts via monoamine 
transporters, remains to be determined. 
 
 
1.4  The noradrenaline transporter 
The neurotransmitter NA, released from noradrenergic neurons of the peripheral or central 
nervous system is a prominent chemical messenger in both systems. The NA transporter (NAT) 
contributes to the termination of action of NA in the synaptic cleft by rapid removal through 
reuptake into the cytoplasm (Iversen 1971; Trendelenburg 1991). The NAT not only regulates 
the longevity of NA in the synapse but also plays a key role in maintaining the presynaptic and 
postsynaptic homeostasis. NET exerts a fine regulated control over NA-mediated behavioural 
and physiological effects including mood, depression, cognition, regulation of blood pressure 
and heart rate.  
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Pathomechanisms associated with the NAT e.g feeding disturbances and depression exhibit the 
NAT as a useful target for therapeutically used drugs. 
 
 
1.4.1  NAT  Structure and Function 
Na+ and Cl- are the two critical ions involved in substrate transport by the NET. Br- is the only 
other ion that can partially mimic the function of Cl-. Other monovalent cations then Na+ are 
not able to take over its unique role (Friedrich and Bonisch 1986). The Na+ gradient based on a 
high Na+ concentration outside and a low Na+ concentration inside the neuron is the main 
driving force across the plasma membrane providing the transport direction from the outside to 
the inside. In addition K+ is creating a negative membrane potential which contributes to the 
translocation mechanism. Both ion gradients are maintained by the key ion pump Na+/K+-
ATPase, which can be blocked by e.g oubain leading to a suppression of NA uptake. 
 
The group of H.Bönisch is suggesting a transport model based on a single centre gated pore 
mechanism with alternating access of the solute to the binding site (Bonisch 1998). In this 
model the empty and mobile carrier is loosing his mobility by first binding the co-substrate 
Na+. Subsequently, the substrate NA and the cosubstrate Cl- are bound resulting  in a regain of 
mobility. After translocation has finished by dissociation of substrate and co-substrates, the 
carrier is returning in its unloaded state to execute a new cycle (Fig. 5). The model proposes 
that NA is translocated as positively charged NA+ and coupling of NA+ transport with Na+ and 
Cl- occurs at a stoichiometry of 1NA+:1Na+:1Cl- (Pifl et al. 1997). 
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Fig . 5: Mechansim of noradrenaline transport.The action of noradrenaline at the synapse is terminated by its re-uptake across 
the pre-synaptic membrane. This is an energy dependent process. Sodium/potassium ATPases use energy from ATP hydrolysis 
to create a concentration gradient of ions across the pre-synaptic membrane that drives the opening of the transporter and co-
transport of 1 sodium and 1 chloride ion  and 1 molecule noradrenaline from the synaptic cleft. Potassium ions binding to the 
transporter enable it to return to the outward position. Release of the potassium ions into the synaptic cleft equilibrates the ionic 
gradient across the pre-synaptic membrane. The noradrenaline re-uptake transporter is then available to bind another 
noradrenaline molecule for re-uptake (www.cnsforum.com/imagebank/item/Rcpt_sys_N_reup_5/default.aspx). 
 
The NAT, the DA transporter and the serotonin transporter belong to the family of Na+/Cl- 
dependent monoamine transporters (Amara 1992). The cloned human NAT cDNA is an 1857 
base pair open reading frame, predicting a protein of 617 amino acids with a mass of 
approximately 69 kDa (Pacholczyk al. 1991). The hNAT protein consitsts of 12 putative 
transmembrane domains (TMs), each of 18-25 amino acids in length (Fig. 6).The amino and 
carboxy termini are both located in the cytoplasmic side. The large extracellular loop between 
TM3 and TM4 has several potential N-glycosylation sites. Glykosylation is strongly involved 
in cell surface expression, e.g a fully glycosylated NAT protein has a greater likelihood of 
being expressed on the cell surface than a poorly glycosylated protein (Melikian et al. 1996). In 
addition to glycosylation sites, there are sites for potential phosphorylation by protein kinase C 
and casein kinase 2 within the intracellular part of the transporter. Experiments using chimera 
constructs between NAT and DAT suggesting that regions from the amino-terminal through the 
first five TMs are likely to be involved in the uptake process and ionic dependence., whereas 
the region from TM4 to TM8 is involved in substrate translocation (Buck and Amara 1994). 
Regions between TMs 6-8 are postulated to determine tricyclic antidepressant binding and 
cocaine interactions.  
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The large extracellular loop also contains two cysteine residues conserverd among all members 
of the family suggesting to play a role in a functional transporter conformation. 
 
 
Fig.6: Schematic presentation of  the hNAT viewed from the front. The typical hNAT has 12 transmembrane spanning 
domains.  The amino and carboxyterminal domain lies in the cytoplasm. Five loops are located intracellulary and six loops 
extracellulary.  The first five TMs are involved in the uptake process, whereas the region from TM4 to TM8 is involved in 
translocation (http://journals.cambridge.org/fulltext_content/ERM/ERM3_29/S1462399401003878sup004.htm). 
 
 
1.4.2  Tissue expression 
NAT mRNA expression is mainly located in the regions where noradrenergic pathways are 
present, respectively the LC complex in the dorsal pons, especially in the nucleus LC proper as 
it is revealed by [3H]nisoxetine binding (Smith et al.  2006). [3H]nisoxetine is a high affinity 
NAT inhibitor used as radioligand. NAT mRNA is additionally expressed in ensemble with 
dopamine-β-hydroxylase mRNA, which is a further marker for NAT expression patterns, in the 
lateral tegmentum of the medulla and pons (Eymin et al. 1995). All these regions inclose most 
of the noradrenergic cell bodies in the central nervous system. Interstingly, moderate 
concentrations of [3H] nisoxetine binding in a serotonergic cell body region, the dorsal raphe 
nucleus have also been reported in rats. This illustrates the interconnections of the central 
noradrenergic and serotonergic neuronal systems. 
 
Arising noradrenergic neurons originating from the locus coeruleus, project to many different 
brain regions and may thus influence complex neural pathways involved in autonomic and 
neuroendocrinal regulation, arousal, attention and affective behaviours like emotion and 
depression. In the periphery a NAT expression can be observed in the placenta the adrenal 
medulla and in sympathetic ganglia.  
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The NAT protein is expressed on noradrenergic cell bodies, dendrites and axons but not 
directly in the active zone of the synapse but more laterally (Schroeter et al. 2000). This has 
been demonstrated for the closely related DAT too. 
 
 
1.4.3  Regulation of NAT function 
NAT function can be regulated in several ways. It may be acutely or chronically depending on 
the stimulus. It may be due to changes in gene transcription, posttranslational modifications 
such as phosphorylation, protein trafficking, cytoskeleton interactions and oligomerization 
(Zahniser and Doolen 2001). A long term change may be due to long-term blockade e.g NAT 
inhibiting antidepressants. Long term application of desipramine was shown to produce up-
regulation of NAT mRNA in the rat locus coeruleus.  
 
In contrast phorbol-ester mediated activation of PKC, whose regulation among monoamine 
transporters seems to be universal, leads to phosphorylation of NAT. This in turn triggers its 
rapid internalisation into the cytoplasm from the plasma membrane. Reduced surface 
expression of NAT is the primary mechanism contributing to PKC-induced decrease in NAT 
activity (Bonisch et al. 1998). 
 
Also neurotransmitters like acetylcholine are altering transporter function by reducing Km but 
not
  
Vmax, thus decreasing NA uptake. Angiotensin II affects blood pressure in the sympathetic 
nervous system which uses NA as neurotransmitter and is interacting with the NAT. A long 
term Angiotensin II triggered activation of the AT1 receptor induces an up-regualtion of NAT 
mRNA through activation of the Ras-Raf-MAP kinase (Lu et al. 1996). Short term Angiotensin 
II exposure leads to an increase of NA uptake by a posttranscriptional event inducing a rapid 
increase in NAT surface expression. The process of NAT movement from the plasma 
membrane is supported by a close localization of synaptic vesicle pools and proteins like 
syntaxin1 and SNAREs with the NAT. 
 
 
1.4.4  NAT inhibitors 
In the nanomolar range the NAT is inhibited by various antidepressants (ADs) such as the 
tricyclic ADs nortryptiline and the ADs reboxetine, nisoxetine and atomoxetine. Among the 
tricyclics desipramine is the most selective one whereas the most selective drug under all 
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mentioned is reboxetine (Kaspar et al. 2000). The psychostimulant cocaine and its 
phenyltropane analogue RTI-55 are also blocking the NAT but are not so selective as they 
additionally block the DAT and the SERT (Olivier et al.  2000). 
 
The high-affinity drugs desipramine and nisoxetine are experimentally used as radioligands 
thus providing density of transporter sites in various tissues. Different studies indicate that 
NAT inhibitors bind to a site at the NAT which is not identical with the substrate recognition 
site but may overlap with it. However, the drug-binding site and the mechanism of this 
inhibition are poorly understood. It is suggested that all blockers have in common that they are 
directly locking the gate, preventing a conformational change, thus inhibiting substrate 
transport (Zhou et al. 2007). 
 
 
1.5  The dopamine transporter 
The DA transporter (DAT) is an integral membrane protein in dopaminergic cells that removes 
DA from the synaptic cleft and reuptakes it into the presynapse where DA is then recycled and 
packed into vesicles in a clathrin dependent process. Because DAT is terminating the DA 
signal it plays a crucial role in DA related disorders like attention-deficit hyperactivity disorder, 
clinical depression, alcoholism and cocaine addiction (Sharp et al. 2009; van der Zwaluw et al. 
2009). 
 
The DA uptake sites interact with MPP+, the active metabolite of the parkinsonism inducing 
drug MPTP, as they represent the preferred port of entry into the dopaminergic cell. Besides of 
pharmacology, the decisive role of DAT was finally revealed by its knockout in mice, 
triggering behaviour similar to ADHD in human. 
 
 
1.5.1 Function and mechanism of dopamine transport 
DAT is a symporter that moves one DA molecule and two Na+ in presence of one Cl across 
the cell membrane by coupling the movement to the energetically favourable movement of 
sodium ions along the concentration gradient into the cell (Fig. 7). In two independent studies a 
fixed binding order of Na+  before DA was observed (McElvain and Schenk 1992). If all three 
binding partners are present, the protein undergoes a conformational change eliciting the 
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translocation step. The lower affinity of DA for the DAT at higher [K+]/ [Na+] ratios in the 
intracellular fluid may favour the dissociation of DA from the DAT on the inside. The 
mechanism for uptake of DA and other biogenic amines is controlled by the transmembranal 
gradient of Na+ and breaks down in a medium in which Na+ is iso-osmotically replaced with 
sucrose, choline or lithium (Syringas et al. 2000). Substitution of Cl with other anions causes 
also a markedly reduced high-affinity uptake. 
 
 
Fig. 7: Mechanism of  dopamine transport.The action of dopamine at the synapse is terminated by its re-uptake across the pre-
synaptic membrane. This is an energy dependent process. Sodium/potassium ATPases use energy from ATP hydrolysis to 
create a concentration gradient of ions across the pre-synaptic membrane that drives the opening of the transporter and co-
transport of  2 sodium and 1 chloride ions and 1 molecule dopamine from the synaptic cleft. Potassium ions binding to the 
transporter enable it to return to the outward position. Release of the potassium ions into the synaptic cleft equilibrates the ionic 
gradient across the pre-synaptic membrane. The dopamine re-uptake transporter is then available to bind another dopamine 
molecule for re-uptake ( www.cnsforum.com/imagebank/item/rcpt_sys_DA_reup/default.aspx). 
 
 
1.5.2  Protein Structure 
The human DAT protein has an estimated size of 68-70 KDa and a 92% overall identity with 
the rat. Its homology with the human NET is 66% followed by 46% with the serotonin and 
42% with the GABA transporter. The DAT is part of a family of Na+-/Cldependent 
transporters which is debilitated in its function without the correct ratio of Na+Cl-/K+ (Nelson 
1998). In biochemical and bioinformatical approaches the structure has been predicted with 12 
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stretches of 20-24 hydrophobic amino acid residues that likely represent membrane spanning 
domains (Fig. 8). The amino and carboxyterminal domain is supposed to be into the cytoplasm. 
The proposed model predicts five intracellular and six extracellular loops between the TMs. N-
glycosylation of the transporter occurs between TM3 and TM4. Two co-ordinating residues in 
the large extracellular loop and in the loop between Tm7 and TM8 has been found which 
provide spatial proximity between the loops (Vaughan 1995; Volz and Schenk 2005). The 
transporter is also intracellulary modified by protein kinase C (third intracellular loop), cAMP-
dependant protein kinase (near the amino terminal domain) and Ca2+-calmodulin-dependent 
kinase (near the carboxyterminal domain). TM2 and TM9 display two leucine zipper motifs, 
structural features that are normally present in DNA-binding proteins mediating protein-protein 
interactions and might be involved in structural organisation of the transporter. The substrat 
binding pocket lies between the second and fourth extracellular loop which are in spatial 
proximity due to histidine residues, building a Zn2+ coordination centre (Loland et al. 2002).  
 
 
Fig. 8:  Schematic presentation of the hDAT viewed from the front. The typical hDAT has 12 transmembrane spanning 
domains.  The amino and carboxyterminal domain lies in the cytoplasm. Five loops are located intracellulary and six loops 
extracellulary.  The substrate binding pocket lies within the  second and fourth extracellular loop which are in spatial proximity 
due to histidine residues, building a Zn2+ coordination centre (Loland et al. 2002) 
 
1.5.3  Uptake blockers 
DAT is also the target for uptake blockers which are strictly speaking drugs which interact with 
the transporter and lock it in a conformation where no translocation in both directions is 
possible. One example is cocaine (Ravna et al. 2003). Under the action of cocaine more DA is 
available in the synapse (Fig. 9) and our reward system is overstimulated eliciting a pleasurable 
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feeling and reinforcement. Self administration experiments of cocaine, performed with rodents, 
show us the addictive potential of this substance. 
 
 
1.5.4  Amphetamine like substances 
All lipophilic and thus centrally active phenylethylamines are belonging to this group. A wide 
range of behavioural processes are affected: motor activity, aggression, sexual behaviour 
learning, memory and self administration are mostly stimulated, whereas sleep, digestion and 
spermatogenesis are suppressed. Amphetamine-like drugs increase the action of both DA and 
noradrenaline in the synapse but are dependent of an intact system of DA or NA neurons. 
 
Amphetamine activity involves several crucial steps (Fig. 9) (Gainetdinov et al. 2002; Sulzer et 
al. 2005). First it enters into the neuron by DAT. Then it penetrates into vesicles via the 
vesicular monoamine transporter 2 (VMAT2) or diffusion and disrupt the vesicular pH 
gradient, which leads to redistribution of vesicular stores of DA into the cytoplasm. 
Amphetamine subsequently reverses the DAT in a process called exchange diffusion. This in 
turn results in a massive outflow of DA to the extracellular space. Additionally amphetamine 
inhibits the monoamine oxidase, giving rise to a higher level of non degraded intracellular DA. 
This results in a raise of DA in the synaptic cleft, which is subsequently released in higher 
doses than under normal conditions. In the presence of DAT blockers amphetamine is not able 
to reverse the action of the DAT. The abusing potential is high and neurotoxic effects were 
demonstrated, especially for methamphetamine.  
 
 
 
Fig. 9: Schematic presentation of cocaine and amphetamine action. Cocaine blocks the DAT thus inhibiting DA reuptake. 
Amphetamine action involves several crucial steps: entry into the neuron and disruption of vesicular pH gradient. Reversial of  
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DAT causes massive outflow of DA by exchange diffusion. Additional inhibition of MAO causes a rise in intracellular non 
degraded DA (Gainetdinov et al. 2002). 
 
As DAT and NAT are electrogenic transporters binding of a transporter substrate will induce 
ion currents whereas an inhibitor will attenuate ion currents. This interplay can be studied by 
patch clamp recordings (Galli et al. 1995, Sitte et al., 1998; Khoshbouei et al. 2003). 
 
 
1.6  Patch clamp 
Patch clamp is a revolutionary method developed by the German neuroscientists Bert Sakmann 
and Erwin Neher (Neher and Sakmann, 1976). In 1991 they had been awarded the Nobel Prize. 
Patch clamping enables one to record ionic currents through single channels or the whole cell. 
This technique is based on a simple idea. A glass pipette with a very small opening is gently 
lowered onto the membrane of a neuron. The pipette contains an Ag/AgCl electrode which is 
connected to an operation amplifier, as well as a pipette solution corresponding to the 
intracellular fluid (Fig. 10). The reference electrode must be placed into the bath solution. The 
aim is to form a tight seal between the underlying patch of membrane and the walls of the 
electrode. It is named Giga-seal so because of its high electrical resistance > 109 Ohm.  
                                
 
After forming the Giga-seal the experimentator sucks on a tube connected with the pipette to 
break through the membrane. Now the whole cell recording mode is produced (Figure 10). The 
interior of the pipette becomes continuous with the cytoplasm of the cell. This mode allows 
measurements of electrical potentials and currents from the entire cell. It allows perfusion with 
different substances to investigate the behaviour of the whole cell. 
 
There are also two other variants which are based on the finding if once there is a tight seal one 
can pull away the membrane with its intracellular surface exposed. This arrangement is called 
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the inside-out patch recording configuration. It allows measuring of single channel currents, 
making it possible to change medium to which the intracellular surface of the membrane is 
exposed. Channels that are activated by intracellular ligands like cAMP can then be studied 
through a range of ligand concentrations. On the other hand, if the pipette is torn away while it 
stays in the whole cell configuration, a membrane patch is produced having its extracellular 
surface exposed. This variant is called the outside-out configuration, which is optimal for 
examining the properties of an ion channel when it is protected from the outside environment, 
but not in contact with its usual environment. The same patch can now be perfused with 
different solutions e.g. neurotransmitter containing ones, and if the channel is intracellulary 
activated a dose response curve can then be studied. 
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2.  Materials and methods 
 
2.1  Cell culture 
The cells used in my experiments are human embryonic kidney 293 cells grown in 
minimum essential medium with Earle’s salts 1-glutamine, 10% heat-inactivated fetal bovine 
serum and 50 mg/l gentamicin on 60 or 100 mm tissue culture dishes (Falcon) at 37°C and 5% 
CO2/95% air. The cells were either transiently or stably transfected with the human DAT, NAT 
or NMDA-receptor subtype NR1/2A.  For the stable expression of hDAT and hNET in HEK 
cells the expression vector pRc/CMV was used as described previously (Pifl et al., 1996). The 
cell lines used were  called 293D13 and 293N17. For most of the patch-clamp experiments and 
for all experiments on NMDA-receptor expressing cells the tetracycline-regulated expression 
system called T-RexTM was used which allowed expression of the proteins in an inducible 
manner. 
 
 
2.1.1. Cells expressing the DAT or NAT in an inducible manner 
T-RexTM is a tetracycline-regulated mammalian expression system that uses regulatory 
elements from the E.coli Tn10-encoded tetracycline (Tet) resistance operon (Fig.11). 
Tetracycline regulation in the T-RexTM system is based on the binding of tetracycline to the Tet 
repressor and derepression of the promoter controlling expression of the gene of interest.  
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Fig.11: Repression of the Tet operator by the Tet repressor (1. and 2.) and induction of transcription by tetracycline (3. and 4.). 
 
The main components of the T-RexTM system include (Fig.12): 
• An inducible expression plasmid, pCDNA4/TO, for expression of a gene of interest under 
the  control of the strong human cytomegalovirus immediate-early  (CMV) promoter and 
two tetracycline operator 2(TetO2)sites  
• A regulatory plasmid, pcDNA6/TR©, which encodes the Tet repressor (TetR) under the 
control of the human CMV promoter 
• Tetracycline for inducing expression 
• A control expression plasmid containing the lacZ gene, which when cotransfected with 
pcDNA6/TR©, expresses β-galactosidase upon induction with tetracycline 
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Fig. 12: Cloning of the gene of interest into the inducible expression vector and cotransfection with the regulatory 
plasmid pcDNA6/TR into mammalian cells. After transfection, cells are treated with tetracycline to derepress the 
hybrid CMV/TetO2 promotor in the inducible expresson vector and induce transcription of the gene of interst. 
 
The cotransfection (see 2. in Fig.12) was done in two consecutive steps. In a first step HEK293 
cells, or HEK293 cells stably expressing the hNAT after transfection with hNAT/pRc/CMV, 
were stably transfected with the regulatory plasmid pcDNA6/TR© which encodes the 
tetracycline repressor protein under the control of the human CMV promoter. The cell lines 
obtained from this first step were cells that we called 293/T-Rex and NAT/T-Rex. In a second 
step these cells were then stably transfected with the expression plasmid pcDNA4/TO 
inducibly expressing the transporter cDNA. For DAT expressing cells only 293/T-Rex were 
used, for NAT expressing cells both, 293/T-Rex and NAT/T-Rex, which should result in a 
particularly high expression level of NAT in case of NAT/T-Rex. 
 
 
2.1.1.1.  Transfection using calcium phosphate 
Two million 293/T-Rex or NAT/T-Rex cells were plated into 100-mm diameter cell culture 
dishes one day before transfection. At the day of transfection, the medium was first changed. 
Six to seven hours later, 5 µg of hDAT/pcDNA4/TO - or hNAT/pcDNA4/TO-DNA in 450µl of 
H2O were mixed with 50µl of 2.5M CaCl2 and 500µl of a solution containing 0.28 M NaCl, 50 
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.1) and 1.5 mM sodium 
phosphate and the total volume of 1 ml was added drop by drop to the 100-mm dish. In the next 
morning a glycerol shock was applied to boost the transfection yield: the medium containing 
Ca-phosphate precipitates was sucked off, the cells were shortly exposed to 1ml of 15% 
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glycerol in PBS, this solution was immediately diluted with 10ml PBS, sucked off and 10ml of 
new medium was added. One day after transfection, cells were split 1:4 and 1 day later 
selection of cells was executed with 0.3 g/l of zeocin (in presence of 5 mg/l of blasticidin) in 
the medium. After 2 to 3 weeks arising cell clones were transferred by sterile 200 µl Gilson 
plastic tips into 48 well plates, later grown up by consecutive splitting into 24- and 6-well 
plates and finally tested for uptake of [3H]DA in 24-well plates as described in chapter 2.3. Out 
of several cell clones displaying specific uptake the clones DAT/TO20, DAT/TO8, NAT/TO17 
(obtained from 293/T-Rex) and N12/TO1 (obtained from NAT/T-Rex) were used for patch-
clamp experiments. 
 
 
2.1.2.   Cell lines expressing the human NR1/2A NMDA receptor   
I generated HEK-cells heterologously expressing a human NMDA receptor  consisting of the 
subunits NR1 and NR2A. Since the expression of the NMDA receptor is cytotoxic I chose the 
inducible expression system T-RexTM. We received the cDNA of the hNR1 subunit inserted 
into the bluescript vector (Dr. Shigetada Nakanishi) and the cDNA of the hNR2A subunit (Dr. 
Antonio Ferrer-Montiel) in an unknown vector which we identified as pcDNAI by sequenzing 
and bioinformatic alignment. A further cloning of the NR2A cDNA into the pcDNA4/TO 
vector appeared to be difficult because of unfavourable restriction sites. Therefore, I undertook 
to subclone the hNR1 into the pcDNA4/TO vector. 
 
 
2.1.2.1.  Subcloning of the NR1 subunit 
The aim was to cut out the gene of the hNR1 subunit out of the bluescript cloning vector and 
insert it into the pcDNA4/TO expression vector. The length of NR1 is 2814 base pairs (bp), 
upstream from ATG there are 422 bp and downstream from TGA there are 1303 bp. This adds 
up to a cDNA of 4539 bp (Fig. 13), a little smaller than the gene with non-coding gene regions 
deposited in genebank (5137 bp). According to restriction sites in bluescript a cut with NotI 
and EcoRI was the most promising because pcDNA4/TO had NotI and EcoRI in the polylinker 
region allowing a directed insertion of NR1with EcoRI ligation upstream and NotI ligation 
downstream. In order to obtain sufficient amounts of phNR1 a maxiprep plasmid extraction 
was done followed by restriction digestions. 
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Fig. 13:  Restriction map of the subunit NR1 in pBluesccript SK(-), a plasmid phNR1 of 7500 bp received by Dr. Nakanishi. 
(Karp et al. 1993) 
 
 
Fig. 14:  Restriction digestion of phNR1 and pcDNA4/to with NOT1 and ECOR1 
 
A cut with Not I linearized phNR1 or, due to the unclear visualization, left it unaffected (Fig. 
14). Cutting with EcoRI+NotI or EcoRI alone resulted in the bigger insert (consistent with 
4539bp) and the smaller vector (consistent with 2961bp), a similar pattern because of the 
vicinity of NotI and EcoRI upstream of NR1.  
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The same treatment of pcDNA4/TO resulted in one big fragment in each case, linearizing by 
the single cuts and cutting out just a few base pairs from the polylinker in case of EcoRI+ NotI. 
 
Further restriction analysis using BclI on phNR1 and BssHII on pcDNA4/TO should give 
information of the ability of NotI to cut phNR1 and EcoRI and NotI to cut pcDNA4/TO (Fig. 
15).  
.
 
Fig. 15: Restriction digestion of phNR1 and pcDNA4/to with different combinations of restriction enzymes.  
 
The double cut by EcoRI+NotI of pHNR1 led again to vector (consistent with 2961bp) and 
insert (consistent with 4539bp). The double cut by NotI+BclI only linearized the construct 
(consistent with 7500pb), obviously BclI was not able to cut in our hands. In agreement with 
this interpretation, the double cut by EcoRI+BclI did not produce three fragments, but a similar 
result as EcoRI+NotI. The double cut of pcDNA4/TO (consistent with 5078 bp) by 
EcoRI+NotI presumably removed 27 bp from the polylinker resulting in one big fragment of 
about 5000 bp. A cut by NotI and BssHII, which is 1240 bp downstream of NotI, produced two 
fragments, the smaller about 1200 bp. The double cut EcoRI+BssHII resulted in similar 
fragments, the shorter one in agreement with the 1267 bp based on the restriction map of 
pcDNA4/TO.  Thus, both EcoRI and NotI are able to open pcDNA4/TO. 
 
Based on this information, the subcloning strategy was to cut out the NR1 from phNR1 by 
EcoRI and ligate it into the pcDNA4/TO between EcoRI sites.  
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Therefore, 3 µg of phNR1 and 3 µg of pcDNA4/TO were cut by EcoRI (Fig.16).  
 
 
Fig. 16: Restrictiondigestion of phNR1 with Hind3 and EcoR1 and pcDNA4/to with EcoR1 
 
The resulting bands, about 4500 bp in case of phNR1 and 5000 bp in case of pcDNA4/TO 
(5078 pb according to Invitrogen), were extracted from the gel using the QIAquick gel 
extraction kit with a final extraction volume of 30 µl. This resulted in about (3000 x 
(4539/7500) x 0.8) = 1452 ng NR1 and in about 3000 x 0.8 = 2400 ng of linearized 
pcDNA4/TO, each in 30 µl, assuming an 80 % extraction yield of the kit.  A 3:1 molar ratio of 
insert:vector was intended for ligation. Therefore, 50 ng of pcDNA4/TO required 134 ng of 
NR1 based on the formula (ng of vector x kb size of insert)/(kb size of vector) x molar ratio = 
(50 x 4539)/5078 x 3 = 134 ng and the ligation was set up by mixing 2.8 µl of extracted insert 
0,65 µl of extracted vector, 4.5 µl H2O, 2 µl of  5x buffer, 10 µl of 2x ligase buffer and 1 µl of 
ligase (5 units/µl). After transformation of JM109 cells, 10 colonies were picked, minicultures 
grown and minipreps analysed for the subcloning product by HindIII digestion (Fig.17). 
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   Fig. 17: Restriction digestion of minipreps with Hind III 
 
After digestion with Hind III minipreps 3, 6 and 9 had 2 fragments which were about 7000 and 
2400 bp long. Based on the restriction scheme in Fig.18 a fragment of 7206 = (5137-
2968+5078-1020+979) bp together with a fragment of 2411 = (2968-598+1020-979) bp would 
indicate the right orientation, whereas 7407 = (2968-598+5078-1020+979) bp and 2210 = 
(5137-2968+1020-979) bp would indicated the wrong orientation.  The slightly bigger 
fragment of about 2400 in miniprep 9 suggests a correct insertion in this case.  
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Fig. 18: Hind III cut of NR1/pcDNA4/TO with correct insertion on the left and the opposite insertion on the right. Outer 
numbers indicate positions of restriction sites within the vector, inner numbers the positions within the insert. 
 
For clarification I decided to do another restriction digestion which produced 3 fragments using 
the enzyme BglII (Fig.19).  
 
 
Fig. 19: Restriction digestion of minipreps 6 and 9 with Bgl II. 
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Based on the restriction scheme in Fig.20 the right orientation would result in three fragments 
of 860 + 1400 + 7357 bp, the wrong orientation in the fragments 860+3433+6184bp. In 
miniprep 6 the 1400 bp fragment was clearly missing, but it was present in miniprep 9, 
indicating the successful subcloning for miniprep 9 (Fig.19).  
 
Fig 20: Bgl II cut of NR1/pcDNA4/TO with correct insertion on the left and the opposite insertion on the right. Outer numbers 
indicate positions of restriction sites within the vector, inner numbers the positions within the insert. 
 
Miniprep 9 was proliferated for further experiments. 
 
 
2.1.2.2. Transient transfection of NR1 and NR2A subunits 
Two million cells were plated into 100-mm diameter cell culture dishes one day before 
transfection. At the day of transfection, the medium was first changed. Six to seven hours later, 
3 µg of NR1/pCDNA4/TO and 3 µg hNR2A/pcDNAI in 450µl of H2O were mixed with 50µl 
of 2.5M CaCl2 and the further transfection procedure was as described in 2.1.1.1.  
 
One day after transfection, induction of the receptor was started by treatment with 1 mg/l 
tetracycline or vehicle as a control. Cells were addtionally treated with 500 µM memantine or 3 
mM Mg2+ to block against cytotoxic effects of the NMDA receptor, or left untreated or treated 
with memantine alone. The cells were harvested for binding two days after transfection. 
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2.1.2.3 Stable transfection of NR1 and NR2A subunits 
For stable transfection I used the cDNA of the subunit NR1 in the expressiong vector 
pcDNA4/TO which allowed selection with the antibiotic zeocin. Since I had to use the cDNA 
of the subunit NR2A in the expression vector pcDNAI without any selection marker, I applied 
5 times more NR2A/pcDNAI than NR1/pcDNA4/TO for cotransfection reasoning that this 
ratio would make it very likely that cells resistant to zeocin would not only express the NR1 
but also the NR2A subunit.  
 
Two million cells 293/T-Rex cells were plated into 100-mm diameter cell culture dishes one 
day before transfection. At the day of transfection, the medium was first changed and six to 
seven hours later, 1 µg of NR1/pCDNA4/TO and 5 µg hNR2A/pcDNAI in 450µl of H2O were 
mixed with 50µl of 2.5M CaCl2 and the further transfection procedure was as described in 
2.1.1.1. One day after transfection, some plates were split 1:8, other plates were split 1:4 to 
reach the right density of cell clone selection. Two days after transfection selecting antibiotics 
were added, zeocin at 0.3 g/l and blasticidin at 5mg/l. After 8 days, medium was changed and 
new blasticidin and zeocin were added. Five days later single clones were identified by putting 
the cell culture plates on a black paper. The clones were sucked off with Gilson pipette tips and 
transferred into 48 well plates pre-filled with 0.5 ml medium per well (+selecting antibiotics). 
Six days later each of the cell clones was split after trypsinisation into one well of a 24-well 
plate and one well of a 48-well plate with respective labelling. On the next day tetracycline was 
added (0.1mg/l) for induction of the NMDA receptor in the 48-well plate. Cell clones dying in 
the 48-well plate (assumingly due to functional NMDA receptor expression) were further 
grown up from the corresponding 24-well plate by consecutive splitting of confluent cell layers 
into 6 well plates and finally 100-mm plates. Cells induced by tetracycline and protected 
against cytotoxic effects by 200 µM memantine were harvested for radioligand binding. 
Uninduced cells and cells induced by tetracycline with and without memantine were visualized 
by phase contrast microscopy using a CCD camera. 
 
2.2.  Patch-clamp experiments 
Thirty to seventy thousand cells were seeded into poly-lysine coated 35 mm tissue culture 
dishes. Cells with inducible transporter were treated with tetracycline at a final concentration of 
0,1mg/l in the medium immediately at seeding (in case of NAT) or on the next day (in case of 
DAT). Two to three days after seeding, the cells were washed twice with bath solution and 
finally incubated in 2 ml of bath solution for 30 min until patch-clamp recordings. 
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 One 35-mm plate was used for about 1-1.5 hours. The bath solution consisted of (mmol/l): 4 
Tris-HCl; 6.25 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES); 120 NaCl; 5KCl; 
1.2 CaCl2; 1.2 MgSO4; 130 NaCl; 34 D-glucose and 0.5 ascorbic acid; pH 7.2. The final 
osmolarity was 300mOsm/l. Patch pipettes were filled with (mmol/l): 130 KCl; 0.1 CaCl2; 2 
MgCl2; 1.1 EGTA; 9 HEPES; 0.65 TRIS; pH 7.2, with an osmolarity of 270 mOsm/l. The 
solutions were sterilized by filtration through a 0.2µm filter and stored for up to two weeks in 
the refrigerator.  
 
 
2.2.1.  Pipette Puller 
Patch electrodes were pulled from borosilicate glass capillaries (GB150F-8P, Science Products, 
Hofhem, Germany) with a programmable Brown-Flaming micropipette puller (P-97; Sutter 
Instruments Co., USA). The ultimate size and shape of a micropipette is determined by the 
parameter values that are programmed by the user. A programm consists of one or more cycles  
which, when executed in sequence, will pull the capillary glass inserted in the instrument 
giving rise to two pipettes. A programm can be up to 8 cycles in length and consists of the 
arbitrary units velocity, time and heat. Heat controls the level of electrical current supplied to 
the filament. The velocity value determines the point at which the heat is turned off and reflects 
the speed at which the two carrier bars are moving during the weak pull. Time controls the 
length of time the cooling air is active. To assess the heat value a ramp test, which is a heating 
point detection, must be started. 
 
After the first melting point is determined the glass capillary is adjusted in a position where the 
glass has not yet been melted. Then the ramp test is started again. This procedure is done three 
times in order to obtain three values from which the median is calculated. The heat setting is 
recommended to be the ramp test value plus 15 units. In my programs the velocity was in a 
range from 23 to 30. The time was always constant at 150 and heat was determined as 
described before.  In Fig. 21 there is an example of a program with four steps. More then one 
step creates a shorter taper and thus a lower pipette resistance. There was no fixed size of 
velocity and heat which always was a little bit of trial and error in order to get pipettes with a 
bellied form in contrast to lance shaped ones which were not optimal.  
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Heat velocity Time 
565 25 150 
565 24 150 
560 23 150 
560 21 150 
Fig. 21:  Example for a puller-program 
 
For receiving pipettes with a smaller opening the glass was slightly melted under the microscop 
with a tungsten filament in a process called heat polishing. Patch electrodes were finally heat-
polished to a tip resistance of 3-9 MΩ.  
 
  
2.2.2  Drug application device 
Test drugs like amantadine and cocaine were applied with a PTR-2000/DAD-12 drug 
application device (ALA Scientific Instruments Inc., Westbury, NY), allowing a complete 
exchange of solutions surrounding the cells under examination within <100ms. During 
measurements cells were continuously superfused with bathing solution. 
 
The DAD system is needed for a programmed application of substances which are filled in 12 
syringes. The liquid column is under constant air pressure. Low voltage digital signals direct 
power to valves to effect open and closed states. In the open state the air pressure forces the test 
substance with a certain concentration through a tube which is connected with the manifold, a 
high tech construct made of 13 capillaries derived from gas chromatography which discharge 
into one small opening. With the manifold the cells are superfused permanently with buffer  
and for a fixed time point with buffer containing the drug of interest. The DAD is connected 
with a PC which allows to be programmed in a way that the valves filled with different test 
drugs are opened and closed for a certain time period until the program ends. The DAD is also 
connected with another PC with the software clampex which assures the recordings of 
previously installed DAD programs.  
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2.2.3.  Voltage clamp mode 
Recordings were performed in the whole cell configuration using an  Axopatch 200B patch-
clamp amplifier and the pClamp data acquisition system (Axon Instruments, Foster City, CA, 
USA) at room temperature (approx. 25°C).  
 
As the patch clamp recording uses a single electrode to voltage clamp the cell, it allows the 
researcher to keep the voltage constant while observing changes in current. The voltage clamp 
configuration is depending on the Ohm's law U=I x R. In the case of a steady voltage you can 
measure the influx as I which is getting higher if the resistance is getting lower according to 
U/R=I. in the voltage clamp modus (V=-70mV) recordings of experiments with different test 
drugs and ligands were performed eliciting or inhibiting an inward current. 
 
 
2.3.  Uptake-experiments 
Cells were seeded in poly-D-lysine-coated 24-well plates (1.3 x 105 DAT/TO cells/well and 1 x 
105 293N17 cells/well) and, 1 day later uptake was performed. The uptake buffer consisted of 
(mmol/l): 4 Tris-HCl; 6.25 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES); 120 
NaCl; 5KCl; 1.2 CaCl2; 1.2 MgSO4; 34 D-glucose and 0.5 Na-ascorbate; pH 7.1. 
Solutions in the multi-well plates were quickly removed using a Pasteur pipette connected to 
vacuum pump with a washing bottle in between and added by a repeating pipette. First, the cell 
culture medium was sucked off. Cells were washed with 500 µl uptake buffer and incubated in 
400 µl buffer. Then 50 µl of a tenfold stock solution of cocaine or amantadine in uptake buffer 
was added. Uptake was initiated by addition of 3 µM [3H]-DA and went on for 2.5 min at 25°C 
on a slide-warmer. Uptake was stopped by sucking off the 500 µl and washing the wells twice 
with 1 ml of ice-cold uptake buffer. Finally, 400 µl of 1% SDS were added to the cells, heated 
in a microwave oven for 20sec, and the SDS solution was transferred into 5ml-minivials using 
a 1ml Gilson pipette. Radioactivity was determined in a liquid scintillation counter after 
addition of 3ml water-miscible scintillation cocktail. For determination of total activity, 50µl 3 
µM [3H]-DA was mixed with 400 µl 1% SDS and 3 ml liquid scintillation cocktail. 
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2.4.  Superfusion 
Cells were seeded onto poly-D-lysine-coated 5-mm-diameter glass coverslips in 96-well tissue 
culture plates at a density of 40000 cells per well. One day later DAT or NAT expressing cells 
were loaded with 6 or 0.5 µM [3H]1-methyl-4-phenylpyridinium (MPP+), respectively, in 50 µl 
uptake buffer at 37°C for 20 min. The coverslips were then transferred into small superfusion 
chambers and superfused with the same buffer as used for uptake experiments (25°C, 1.0 
ml/min). After a wash out period of 45 min to establish a stable efflux of radioactivity, the 
experiment was started by collecting 4-min fractions into 20-ml tubes using a fraction collector. 
Three fractions were collected to obtain a baseline value, then superfusion was switched to a 
buffer containing the various drugs of interest for 3-4 fractions. At the end of the experiment 
superfusion of 1 % SDS eluted the total radioactivity in the cells on the coverslip. The 
radioactivity in the superfusates and the SDS-lysates was determined by liquid scintillation 
counting after addition of 6 (buffer fractions) to 10.5 ml (SDS-fractions) scintillation cocktail. 
The radioactivity released during a specific 4min fraction was expressed as percentage of the 
total radioactivity present in the cells at the beginning of each fraction by adding up 
radioactivity in the respective and all following fractions including the SDS-fraction.  
 
 
2.5.   Radioligand binding on NMDA receptor expressing cells 
For harvesting 3x 100 mm plates were put on ice, cell culture medium was sucked off, cells 
were washed with 10 ml PBS and 5 ml PBS was added to each plate. Then cells were scraped 
from the first plate in 5 ml PBS and transferred into a 50 ml falcon tube. This was repeated for 
the remaining plates. Then the three plates were consecutively rinsed with 5 ml PBS and this 
added up to a total of 20 ml cell suspension which was centrifuged for 10 min at 2400rpm. The 
pellet was re-suspended in 30 ml of buffer (50mM Tris-acetate, pH 7.0), and centrifuged for ½ 
hour at 4°C with 17000rpm in a SS34-rotor. The resulting pellet was resuspended in 500 µl 
buffer and frozen at -80 °C.  
 
For the binding assay, frozen samples were replenished with 10 ml buffer in SS34-tubes, 
homogenized with a repeating pipette and finally filled up to 35 ml with buffer and centrifuged 
30 min at 17000 rpm. Pellet was resuspended in 500 µl buffer with the repeating pipette 
resulting in the final membrane preparation. Three hundred µl of buffer, 50 µl of 100µM 
glutamate/glycine, 50 µl of 50nM [3H]MK801 and 100 µl membrane preparation were mixed 
and incubated for 2h at 24°C.  
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For unspecific binding 50 µl of a mixture of 100µM CGP39653(Ciba Geigy)/10 µM 
L701324(Merck Sharp & Dohme) instead of glutamate/glycine was used. 
 
Incubation was stopped by addition of 4 ml of ice-cold buffer and rapid filtration through 
Whatman GF/B Filters presoaked for 1h in polyethylenimine (0.3% in H20), using a 48-place 
Brandel (Gaithersburg, MD) harvester. Filters were washed twice with 4ml ice-cold buffer and 
transferred into counting vials. 1.8 ml of scintillation cocktail was added and vials shaked 
vigorously. Thereafter vials were agitated for 20min. Two samples with 1.8 ml of scintillation 
cocktail and 50 µl of 50nM [3H]MK801 were prepared for measurement of total activity. 
Radioactivity was counted with liquid scintillation counter. 
 
The protein content of the membrane preparation was determined by the Bio-Rad Protein assay 
based on the method of Bradford. Since the membrane preparation was diluted 1:10 in water, 
the protein standard (bovine serum albumine,  BSA) was dissolved in 5mM Tris-acetate. Five 
dilutions containing 2, 4, 8 , 12 and 16 µg BSA/50 µl were prepared. The assay was performed 
in duplicates by mixing 750µl H2O with either 50µl 5mM Tris-acetate for autozero or 50µl 
standard solution or 50µl 1:10 diluted membrane preparation and 200 µl of dye reagent 
concentrate in photometer vials and incubation for 20 min at room temperature. Absorbance of 
samples was measured at 595nm. 
 
 
2.6.  Cell viability assay 
Cell viability was determined in 96 well plates. Five thousand cells were seeded in 200 µl 
medium per well. One day later the NAT or the NR1/2A receptor was induced by tetracycline 
at a final concentration of 0.1mg/l by adding 2µl of a 100x stock to 200µl medium and the cells 
were exposed to various drugs (desipramine, amantadine, ketamine ..) by adding 4µl of a 50x 
stock to 200 µl medium or H2O as vehicle. Toxicity in NAT expressing cells was induced by 
adding 2µl of a 100x stock to 200µl medium to obtain a final concentration of 1µM MPP+. 
Two µl H2O was added as vehicle. The application scheme for the various drugs is shown in 
Fig.22 
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Fig. 22:  Application scheme of substances for hNAT expressing cells in 96-well plates. Cells in the first column of wells on 
the left were not induced (-tet), all other wells were treated with 0,1mg/l tetracycline (tet.). Column of wells were treated with 
vehicle (V) or increasing concentrations of desipramine or amantadine as indicated. Four rows of wells (yellow) were treated 
with 1 µM MPP+ as toxic agent or stayed untreated (vehicle, blue).  
 
Toxicity in NR1/2A cells was observed one day after receptor induction presumably due to 
glutamate in the culture medium. The application scheme for the various drugs is shown in 
Fig.23 
 
 
                   
 
Fig. 23:  Application scheme of substances for NR1/2A expressing cells in 96-well plates. Column of wells were treated with 
vehicle (V) or increasing concentrations of amantadine or ketamine as indicated. Four rows of wells were treated with 
tetracycline for induction of toxicity mediated by expression of the NMDA receptor (tet., green) or stayed untreated (vehicle, 
blue).  
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Three days after administration of drugs to NAT-cells and one day after administration of drugs 
to NR1/2A-cells the number of living cells was estimated by measuring acid phosphatase 
activity according to Yang and coworkers (1996). First, cells were washed with 200 µl PBS. 
Then cells were incubated with 100 µl of NPP buffer (0.8232 mg p-nitrophenylphosphate + 9.9 
ml H2O + 1.1ml 1 M sodiumacetate, pH 5.4, in 1 % triton X-100). Fourty eight wells were 
handled in a row. Incubation was at 37°C for two hours. The reaction was stopped by addition 
of 10µl of a 1M NaOH solution. Absorbance was measured at 405 nm in the microplate reader. 
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3.  Results 
 
3.1.  Uptake experiments on NAT or DAT expressing cells 
Several publications reported effects of amantadine on monoamine neurotransmission in 
rodents (see chapter 1.3.). Therefore, it seemed to be interesting to investigate the effect of 
amantadine for the first time on the human NAT and DAT. First, the uptake of [3H]DA was 
measured in NAT and DAT expressing cells in presence of increasing concentrations of 
cocaine and amantadine (Fig. 24). 
 
 
Fig. 24:  Uptake of DA in HEK-cells expressing the human DAT (open symbols) and the human NAT (closed symbols) under 
increasing concentrations of cocaine and amantadine as indicated. Symbols represent means +/- standard error of n independent 
experiments, each in duplicates. n=10 for amantadine in DAT, n=6 for cocaine in DAT, n=8 for amantadine in NAT, n=4 for 
cocaine in NAT.  The data of each experiment were fitted by nonlinear regression. 
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Amantadine was able to block the uptake by the NAT or DAT in a concentration-dependent 
manner and had a 15 fold higher potency for blocking the NAT than the DAT. Cocaine, as 
positive control, was nearly equipotent at the DAT and NAT and about 15 fold more potent 
than amantadine at the NAT.  
 
 
3.2.  Release experiments on NAT expressing cells 
The effect of amantadine in uptake experiments could be due to pure uptake inhibition similar 
to the action of cocaine, or due to a releasing action. Therefore, the effect of amantadine was 
studied in superfusion experiments and its effect was compared to amphetamine as a positive 
control (Fig.25). 
 
 
 
Fig. 25:  Superfusion of HEK293 cells stably expressing the human NAT grown on 5-mm-diameter coverslips and preloaded 
with [3H]MPP+. Effects of amphetamine and amantadine induced release of [3H]MPP+ at the concentrations indicated. Bar 
indicates fractions after exposure to amphetamine or amantadine. Symbols represent means +/- standard error of three 
independent experiments. 
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In these superfusion experiments one can clearly see that amantadine acted as a releasing drug, 
however its intrinsic activity was about half of that of amphetamine as the maximally induced 
tritium efflux was 4% per 4 min fraction as compared to 9% per 4 min fraction induced by 
10µM amphetamine, a concentration of amphetamine which is nearly maximally active as 
reported previously (Sitte et al., 1998). 
 
The releasing effect of 100 µM amantadine was completely suppressed by the presence of 10 
µM mazindol (Fig.26) 
 
Fig. 26: Superfusion of HEK293 cells stably expressing the human NAT grown on 5-mm-diameter coverslips and preloaded 
with [3H]MPP+. Bars indicate fractions after exposure to mazindol or amantadine. Symbols represent means +/- standard error 
of 3 independent experiments.  
 
This concentration of mazindol also blocked the releasing effect of 10 µM amphetamine 
completely (Fig. 27). 
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Fig. 27:  Superfusion of HEK293 cells stably expressing the human NAT grown on 5-mm-diameter coverslips and preloaded 
with [3H]MPP+. Bars indicate fractions after exposure to mazindol or amphetamine. Symbols represent means +/- standard 
error of 3 independent experiments.  
 
 
3.3. Patch-clamp experiments 
 
3.3.1. Patch-clamp experiments on NAT expressing cells 
The type of interaction of a substance with plasmalemmal neurotransmitter transporters can be 
investigated by the patch-clamp technique. Therefore, I voltage-clamped HEK293 cells 
expressing the human NAT in the whole-cell configuration. In a first series of experiments the 
effects of NA and amanatadine, each administered alone, were investigated. (Fig. 28). 
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Fig. 28: Effects of amantadine on whole-cell patch-clamp recordings of HEK293 cells stably and inducibly expressing the 
human NAT. The cells were voltage-clamped at a holding potential of -80mV and superfused at the times marked by the bars 
for 4 s with noradrenaline and amantadine at the concentrations indicated. Shown are mean values of current traces ± SEM 
(grey area) of 19 cells. * p < 0,02 versus first NA-induced inward current by paired Student’s t-test.. 
 
 
After a forerun of buffer lasting for 8 seconds 30µM NA was superfused for 4 seconds causing 
an inward current of about 60pA. Repeated superfusion of amantadine for 4 seconds with 
buffer for 8 seconds in between, led to an inward current of about 10 pA. A second superfusion 
with 30µM NA also triggered an inward current which was significantly smaller (45 pA) than 
the first one which might be due to a phenomenon of desensitization in these experiments.  
 
In another program of superfusion, the effects of NA and amantadine, which were administered 
alone and together, were investigated (Fig. 29). 
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Fig. 29: Effects of amantadine on whole-cell patch-clamp recordings of HEK293 cells stably and inducibly expressing the 
human NAT.  The cells were voltage-clamped at a holding potential of -80mV and superfused at the times marked by the  bars 
for 2 s with 30 µM amantadine or 10 µM NA. Shown are mean values of current traces ± SEM (grey area) of 15 cells. * p < 
0,0005 versus NA-induced inward current in the presence of 30 µM amantadine. 
 
A 2-second switch of superfusion from one buffer-containing syringe to another buffer- 
containing syringe did not induce any change of current. Superfusion with 30 µM amantadine 
induced an inward current of about 10 pA, and 10 µM NA in the continued presence of 
amantadine caused an additional inward current of about 10 pA. The following 3 repetitions of 
2-second superfusions with 10µM NA alone led to an influx of about 25pA without signs of 
desensitization. These experiments demonstrate an attenuating effect of amantadine on NA-
induced inward currents. 
 
If currents induced by NA and modified by amantadine are related to the NAT it should be 
affected by the NA uptake blocker cocaine. Therefore, I investigated the effect of cocaine in the 
next series of experiments (Fig.30).  
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Fig. 30: Effects of cocaine on whole-cell patch-clamp recordings of HEK293 cells stably and inducibly expressing the human 
NAT. The cells were voltage-clamped at a holding potential of -80mV and superfused at the times marked by the bars for  2 s  
with 30 µM cocaine and/or 10 µM noradrenaline. Shown are mean values of current traces ± SEM (grey area) of 14 cells. 
 
 
A forerun of buffer for 8 seconds was followed by a 2-second superfusion of 30µM cocaine 
and a subsequent application of 10µM NA in the continued presence of 30 µM cocaine. 
Cocaine induced a small outward current of about 5-10pA which can be explained by blockade 
of a leak current in NAT-expressing cells.  In the presence of cocaine NA was without effect, 
however the blocking action of cocaine could be washed out since after 8 seconds of buffer 
three repeated applications of 10µM NA for 2seconds each elicited inward currents of about 30 
pA. 
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3.3.2. Patch-clamp experiments on DAT expressing cells 
First the effect of amantadine was compared with that of DA (Fig.31).  
 
 
Fig. 31:  Effects of Am on whole-cell patch-clamp recordings of HEK293 cells stably and inducibly expressing the DAT. The 
cells were voltage-clamped first at a holding potential of -80mV and  superfused at the times marked  by the  bars  for  4 s with 
DA or Am at the concentrations indicated. Shown are mean values of current traces ± SEM (grey area) of 7 cells. 
 
After an 8-second forerun of buffer, superfusion of 10µM DA for 4 seconds elicited an influx 
of about 40 pA. After a washout with buffer for 8 seconds repeated administration of 10µM 
amantadine for 4 seconds had no significant effect and application of 10µM DA for 4 seconds 
at the end of the superfusion program led again to an inward current of approx. 40 pA. 
Since amantadine had no effect on the DAT on its own, the question was weather it modified 
the effect of a transporter substrate on the DAT.  Therefore, I designed a superfusion program, 
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Fig. 32:  Effects of Am on whole-cell patch-clamp recordings of HEK293 cells stably and inducibly expressing the DAT. The 
cells were voltage-clamped first at a holding potential of -80mV and superfused at the times marked by the bars for 
2 s with Am or Am in presence of NA or NA alone at the concentrations indicated. Shown are mean values of current traces ± 
SEM (grey area) of 10 cells. p>0,05 versus first inward current of NA in presence of Am. 
 
where I could assess the effect of amantadine and NA alone and a combination of both (Fig. 
32). After a forerun of buffer for 8 seconds superfusion with 30 µM amantadine for 2 seconds 
induced a minor, transient inward current and subsequent superfusion of 10 µM NA in the 
continued presence of 30 µM amantadine elicited an inward current of about 30 pA. After 
buffer washout three 2-second applications of NA (alternating with 8-second applications of 
buffer) led to an inward current of about 40 pA which was significantly higher than the effect 
of the combination of NA with amantadine. This hints to a small blocking effect of amantadine 
on the DAT. 
 
This DAT blockade was much weaker than that by the prototypic DAT blocker cocaine. In my 
last patch-clamp experiment the effect of cocaine alone and its effect on the DAT substrate NA 
was investigated (Fig.33). 
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Fig. 33:  Effects of cocaine on whole-cell patch-clamp recordings of HEK293 cells stably and inducibly expressing the DAT. 
The cells were voltage-clamped first at a  holding  potential  of -80mV   and    superfused at   the times   marked by the bars for  
2 s with cocaine or cocaine in presence of NA or NA alone at the concentrations indicated. Shown are mean values of current 
traces ± SEM (grey area) of 12 cells. 
 
A forerun of buffer for 8 seconds was followed by superfusion of 30 µM cocaine for 2 seconds, 
a subsequent combination of 30 µM cocaine with 10 µM NA for another 2 seconds and, after a 
8-second washout with buffer, three repeated applications of 10 µM NA, 2 seconds each, with  
8 seconds of buffer in between. Cocaine elicited as small outward current of less than 10 pA 
similar to its effect at NAT expressing cells. The combination of cocaine and NA was 
essentially baseline and after a washout with buffer for 8 seconds the repeated NA applications 
led to inward currents of about 30pA revealing a total recovery of the NAT function after 
cocaine is washed away.  
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3.4.  Characterization of cells expressing the human NR1/2A receptor 
 
3.4.1.  Radioligand binding after transient transfection 
First I cotransfected equal amounts of the subunits NR1- and NR2A-cDNA into 293/T-Rex 
cells and assessed the formation of functional receptors by binding of the radioligand [3H]MK-
801 to membranes prepared from these cells. 
 
Specific binding in fmol/tube 
uninduced 0.696 
receptor induced 16.94 
hippocampal membranes 39.16 
 
Table 1:  Binding results of transient transfection. 
 
Due to variable amounts of protein per tube (2.5 µg in uninduced cells, 58.8 µg in induced 
cells, and 36.9 µg in hippocampal membranes) specific binding per mg protein was not higher 
in induced than in uninduced cells after transient transfection.  
 
 
3.4.2.  Cytotoxicity after stable transfection 
Cell clones surviving the selecting antibiotic were grown up and on each clone the effect of 
induction by tetracycline on viability was determined. Effects of receptor-induction by 
tetracycline and the protective effect of the NMDA-receptor antagonist memantine was 
visualized in selected clones seeded in a 24- and a 12-well plate by phase contrast microscopy 
(Fig.34 and Fig.35). 
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Fig. 34:  Phase contrast microscopy of different clones in a 24-well plate after induction with tetracycline in the absence or 
presence of 200 µM memantine as well as without induction as a control.   
 
Fig.35:  Phase contrast microscopy of different clones in a 12-well plate after induction with tetracycline in the absence or 
presence of 200 µM memantine as well as without induction as a control. 
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Induction of the receptor by tetracycline induced cell death with round, partly floating cells 
loosing their processes and connections to other cells (Fig. 34 and 35). The presence of 200 µM 
memantine provided protection against NMDA receptor mediated autotoxicity and the cells 
resembled the control cells not induced by tetracycline.  
 
 
3.4.3.  Radioligand binding after stable transfection 
Cell clones showing cell death induced by tetracycline were induced in the presence of 
cytoprotective memantine and harvested for radioligand binding. Cell membranes prepared 
from human post mortem brain (fronto-parietal cortex) were used as a positive control. 
The results for the different clones are summarized from two binding experiments in Table 2. 
 
         
Protein amounts per tube 
clone 1                            117.2 µg 
clone 8                                4.8 µg 
clone 12 24 µg 
clone 22                               116 µg 
clone 27 84 µg 
clone 29                              24.4 µg 
clone 71                              77.6 µg 
clone 76 70 µg 
clone 82 84 µg 
clone 83 96 µg 
frontoparietaler cortex (+control)                               138 µg 
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Specific binding (pmol/mg protein) 
clone 1 0,009 
clone 8 1,61 
Clone12 no specific binding 
clone 22 0,017 
clone 27 0,076 
clone 29 0,275 
clone 71 0,003 
clone 76 0,009 
clone 82 0,017 
clone 83 0,031 
frontoparietaler cortex (+control) 0,629 
 
Table 2:  Protein amounts and specific binding in different cell clones with inducible expression of the NR1/2A receptor and 
human cortical membranes as a positive control. 
 
Specific binding varied considerably between cell clones and was much lower than in human 
cortex, except for clone 29. The result for clone 8 is not reliable due to the small amount of 
protein. 
 
 
3.5.          Toxicity assays on NAT or NR1/2A-receptor expressing cells   
In order to determine the potency of amantadine on the NAT and the NR1/2A-receptor under in 
vivo conditions, I used a cytotoxicity model where blockade of the NAT or the NR1/2A-
receptor produced a concentration-dependent cytoprotective effect.  
 
3.5.1.  MPP+-induced cytotoxicity in NAT expressing cells    
NAT expressing cells were treated with 1 µM MPP+ which enters the cells through the NAT as 
a gate and decreases cell viability as described previously (Pifl et al., 1996). Treatment of the 
cells with drugs blocking the NAT increased cell viability in a concentration-dependent 
manner. The unselective DA and NA uptake blocker mazindol was tested in the range of 0.03 
and 10 µM (Fig.36). 
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Fig. 36:  Effect of mazindol on MPP+-induced toxicity in NAT expressing cells. Cells expressing the NAT under the control of 
the T-Rex™ were seeded in 96-well plates and one day later the NAT was induced by treatment with tetracycline, cells were 
treated with mazindol at the concentrations indicated and toxicity was elicited by 1 µM MPP+. Cell viability was determined by 
measuring acid phosphatase activity 3 days later. Activity was measured in quadruplicates and expressed as percentage of that 
of vehicle-treated cells. Symbols represent mean values ± SEM of 2 separate experiments. 
 
At 1 µM there was a weak, at 10 µM mazindol a clear protection against MPP+.  
 
In another series of experiments the selective NAT blocker desipramine was tested in the same 
range of 0.03 to 10 µM (Fig.37). In these experiments, MPP+ had a stronger cytotoxic effect 
decreasing cell viability to 40 % of that of vehicle treated cells.  
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Fig. 37:  Effect of desipramine on MPP+-induced toxicity in NAT expressing cells. Cells expressing the NAT under the control 
of the T-Rex™ were seeded in 96-well plates and one day later the NAT was induced by treatment with tetracycline and 
desipramine was added at the concentrations indicated and induction of toxicity by 1 µM MPP+. Cell viability was determined 
by measuring acid phosphatase activity 3 days later. Activity was measured in quadruplicates and expressed as percentage of 
that of vehicle-treated cells. Symbols represent mean values ± SEM of 5 separate experiments.    
 
Desipramine increased cell viability in a concentration-dependent manner with weak effects at 
0.1 and 0.3 µM and nearly restored cell viability at 10 µM.  
 
I tested the ability of amantadine to protect NAT expressing cells against MPP+ cytotoxicity in 
the concentration range of 3 to 300 µM (Fig.38). 
 
 
Fig. 38:  Effect of amantadine on MPP+-induced toxicity in NAT expressing cells. Cells expressing the NAT under the control 
of the T-Rex™ were seeded in 96-well plates and one day later the NAT was induced by treatment with tetracycline, 
amantadine was added at the concentrations indicated and toxicity was elicited by 1 µM MPP+. Cell viability was determined 
by measuring acid phosphatase activity 3 days later. Activity was measured in quadruplicates and expressed as percentage of 
that of vehicle-treated cells. Symbols represent mean values ± SEM of 9 separate experiments.       
 
Amantadine increased cell viability in a concentration-dependent manner, there was no effect 
up to 30 µM, a significant protection at 100 µM (p < 0.05 by Student’s t-test) and at 300 µM 
cell viability was increased to about 80 % of untreated cells.  
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3.5.2.  NR1/2A-receptor induced cytotoxicity 
In cells expressing the NR1A/2A receptor under the control of the T-RexTM system cytotoxicity 
was induced by treatment with tetracycline, eliciting the synthesis of NMDARs which are 
excitotoxic presumably due to constant Ca2+ influx into the cell triggering apoptosis.  
 
Treatment of the cells with drugs blocking the NMDA receptor increased cell viability in a 
concentration-dependent manner.The noncompetitive antagonist at the NMDA receptor 
ketamine was tested in the concentration range of 3 to 1000 µM (Fig.39). 
 
                   
Fig. 39:  Effect of ketamine on toxicity induced by NMDA receptor expression. Cells expressing the NR1/2A-receptor under 
the control of the T-Rex™ were seeded in 96-well plates and on the next day the NR1/2A-receptor was induced by treatment 
with tetracycline and ketamine was added at the concentrations indicated. Cell viability was determined by measuring acid 
phosphatase activity 24 hrs after treatment. Activity was measured in quadruplicates and expressed as percentage of the activity 
in uninduced cells. Symbols represent mean values ± SEM of 3 separate experiments. 
 
Ketamine increased cell viability in a concentration-dependent manner at concentrations up to 
300 µM which restored viability to more than 90 % of uninduced cells. At 1000 µM a marked 
reduction in viability to 70 % was observed.  
 
In another series of experiments I tested the nonkompetitive antagonist memantine in the 
concentration-range of 1 to 300 µM (Fig.40). 
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Fig. 40:  Effect of memantine on toxicity induced by NMDA receptor expression. Cells expressing the NR1/2A-receptor under 
the control of the T-Rex™ were seeded in 96-well plates and one day later the NR1/2A-receptor was induced by treatment with 
tetracycline and memantine was added at the concentrations indicated. Cell viability was determined by measuring acid 
phosphatase activity 24 hrs after treatment. Activity was measured in quadruplicates and expressed as percentage of that of 
uninduced cells. Symbols represent mean values ± SEM of 3 separate experiments. 
 
Memantine increased cell viability concentration dependently reaching a maximum protective 
effect at 100 µM with a viability of about 90 % of uninduced cells. 
 
Finally, I tested amantadine for its protective action against NMDA-receptor induced 
cytotoxicity in the concentration range of 1 to 300 µM (Fig. 41). 
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Fig. 41:  Effect of amantadine on toxicity induced by NMDA receptor expression. Cells expressing the NR1/2A-receptor under 
the control of the T-Rex™ were seeded in 96-well plates and one day later the NR1/2A-receptor was induced by treatment with 
tetracycline and amantadine was added at the concentrations indicated. Cell viability was determined by measuring acid 
phosphatase activity 24 hrs later. Activity was measured in quadruplicates and expressed as percentage of that of uninduced 
cells. Symbols represent mean values ± SEM of 4 separate experiments. 
 
Amantadine had no significant effect in concentrations up to 100 µM. At 300 µM amantadine 
significantly antagonized the NMDA-receptor induced cytotoxicity (p < 0.05 by Student’s t-
test), but only restored cell viability to about 70 % of uninduced cells.  
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4.  Discussion 
 
Back in the 1960s amantadine was only used for the prophylaxis and treatment of influenza A 
acting as an inhibitor of a viral integral membrane protein necessary for uncoating. Later on in 
the 1970s observations showed that amantadine was beneficial for the treatment of PD, as it 
could substantially reduce Parkinsonian symptoms. Today amantadine is a standard first line 
therapy in PD and is administered together with levodopa and DA receptor agonists and 
muscarinreceptor antagonists. Besides of its weak NMDAR blocking properties amantadine 
has been shown in several studies to increase extracellular DA and NA levels. 
 
Since plasmalemmal monoamine transporters are decisively involved in the regulation of 
extracellular NA and DA concentrations, the scope of my work was to compare the action of 
amantadine on NAT and DAT with its action on the NMDA receptor. Furthermore, for the first 
time the interaction of amantadine with the human variants of these proteins should be studied. 
Finally, the interaction should be investigated on living cells in order to reproduce in vivo 
conditions for the human proteins. In contrast to radioligand binding assays, which would be 
another option to study the molecular pharmacology of a drug, assays on living cells have the 
advantage that transporters or receptors are embedded in their natural environment in terms of 
ion distribution and membrane potential.  
 
For investigation of the role of amantadine as a possible releaser of NA and DA I used 
HEK293 cells which heterologously expressed the human NAT or DAT. In uptake experiments 
amantadine was able to block the transport of radiolabelled substrates into both types of cells. 
However, amantadine was 15 times more potent in inhibiting uptake by the NAT than by the 
DAT. Also in previous work on rat brain preparations amantadine was more potently inhibiting 
uptake into NA than into DA rich regions (Herblin 1971; Baldessarini et al. 1972; Thornburg 
and Moore, 1973). The next question was if amantadine was a pure uptake inhibitor or a 
releasing drug, because both, uptake blockers and releasing drugs, behave similar in uptake 
experiments. Therefore, I did superfusion experiments by which I was able to distinguish 
between both types of drugs. In superfusion experiments on NAT expressing cells, amantadine 
clearly demonstrated a releasing action however the maximum effect was less than half of that 
of amphetamine. The pure uptake inhibitor mazindol was able to block the releasing action of 
both, amphetamine and amantadine. This finally confirmed that amantadine is a releaser like 
amphetamine.  
  66 
 
Recent studies on amphetamine research show that reverse transport is dependent on 
intracellular phosphorylation of the N-terminus of DAT (Khoshbouei, Sen et al. 2004). 
Amphetamine-induced reverse transport is also abolished in NAT if there is no phosphorylation 
of the N-terminus (Kantor, Hewlett et al. 2001). Amphetamine induced activation of PKC and 
CaMKII seems to be crucial for the phosphorylation of the N-terminus which leads to the 
association of syntaxin1A. All these factors together promote the shift of DAT from a reluctant 
state to a willing state for amphetamine-induced DA-efflux (Robertson, Matthies et al. 2009). 
With special inhibitors of PKC and CaMKII (staurosporine) or Syntaxin 1 A in DAT and NAT 
expressing cells with subsequent superfusion with amantadine and amphetamine as control it 
could be clarified in future experiments if amantadine acts through the same intracellular 
mechanisms as amphetamine. 
 
Patch-clamp experiments are another approach to elucidate the type of drug interaction with a 
transporter. The translocation process in the DAT or NAT is an electrogenic process because 
the cotransport of sodium ions results in the influx of one or two positive charges for each 
molecule of DA or NA pumped into the cell. Additional ion fluxes might be due to a channel-
like mode of the transporters triggered by the interaction with substrates as suggested in several 
reports. Releasing drugs behave like transporter substrates and induce inward currents in 
voltage-clamp experiments in the whole-cell configuration. Therfore, my patch-clamp 
experiments also revealed that amantadine was a releasing drug at the NAT. Ten and 30 µM 
amantadine induced inward currents. These currents were smaller than that induced by 
amphetamine. This is in agreement with the weak releasing action of amantadine in superfusion 
experiments. The question, if the maximum inward current to be elicited by amantadine is also 
smaller than that elicited by amphetamine, would require data on higher concentrations of 
amantadine in patch-clamp experiments. However, the finding that the NA-induced inward 
current was smaller in the presence of amantadine suggests that amantadine is in fact a kind of 
“partial releaser”, following the concept of partial agonism in receptor pharmacology, where 
drugs are called partial agonists if they stimulate signal transduction at receptors, but to a 
smaller extent than full agonists. 
 
The superfusion of 10 µM amantadine on DAT cells produced no significant inward currents 
and the application of 10 µM NA in the presence of 30 µM amantadine led to a negligible 
attenuation of the NA evoked inward current (p>0.05) at the DAT. These findings suggest that 
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amantadine has a lower affinity at the DAT than at the NAT and are in agreement with the 
uptake data. 
 
To study the interaction of amantadine with a human NMDA receptor I established cell lines 
stably expressing a receptor consisting of the two subunits NR1 and NR2A, which are most 
widely distributed in the brain (Mori and Mishina, 1995), under the control of the T-RexTM 
system. Although binding of the radioligand MK801 by the various clones was rather weak 
compared to brain tissue, the NMDA receptor was functionally active as revealed by the strong 
toxicity if the receptor was induced in cells. The well-known noncompetitive NMDA-receptor 
antagonist ketamine efficiently blocked cytotoxicity in the µmolar range restoring cell viability 
to more than 90 % of that of cells without NMDA-receptor induction. By contrast, amantadine 
was not protective at 100 µM and only partly at 300 µM. 
 
In the cytotoxicity paradigm actions of the drugs in a time scale of more than 24 hrs are 
relevant. In order to study long-term blocking effects on the NAT as well, I investigated the 
interference of amantadine with the cytotoxic effect of MPP+ on NAT expressing cells. In this 
model the highly NAT-selective tricyclic antidepressant drug desipramine had the highest 
potency and efficacy in blocking the MPP+-induced toxicity. Amantadine was much less potent 
than desipramine, but 100 µM had a significant, and 300 µM a strong protective effect, 
restoring cell viability to 80 % of vehicle treated cells. It is interesting to note that in the 
superfusion experiment there was no difference between the releasing effect of 100 µM and 
300 µM amantadine whereas in the toxicity assay 300 µM amantadine were clearly more 
effective. The mechanism of cytoprotection is the blockade of the MPP+ transport into the cell, 
whereas for induction of release amantadine acts as substrate and induces reverse transport.  
In conclusion, based on my results, amantadine is at least as potently inhibiting the human 
NAT as blocking the human NMDA receptor. Although my experiments on transfected cells 
obviously could not definitely establish amantadine’s mode of action in PD, the molecular 
pharmacology as demonstrated in my work is not incompatible with a noradrenergic 
mechanism. 
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